Biotech · Private company
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Track this companyFree. Adds Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Efprezimod alfaPhase 3 · Hematopoietic Stem Cell TransplantationClinicalTrials.gov · fetched Nov 12, 2026
- Efprezimod alfaPhase 3 · Coronavirus Disease 2019 (COVID-19)ClinicalTrials.gov · fetched Nov 12, 2026
- MethotrexatePhase 3 · Hematopoietic Stem Cell TransplantationClinicalTrials.gov · fetched Nov 12, 2026
- TacrolimusPhase 3 · Hematopoietic Stem Cell TransplantationClinicalTrials.gov · fetched Nov 12, 2026
- CD24FcPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Efprezimod alfaPhase 2 · Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)Phase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- MethotrexatePhase 2 · Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Metastatic MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- TacrolimusPhase 2 · Graft Versus Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Efprezimod alfaPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)PHASE1_PHASE2 · WITHDRAWN · started Jun 15, 2021ClinicalTrials.gov NCT04060407 · fetched Nov 12, 2026
- Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)PHASE3 · TERMINATED · started Jan 5, 2021ClinicalTrials.gov NCT04095858 · fetched Nov 12, 2026
- CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC StudyPHASE1_PHASE2 · TERMINATED · started Oct 30, 2020ClinicalTrials.gov NCT04552704 · fetched Nov 12, 2026
- Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)PHASE2 · TERMINATED · started Aug 31, 2020ClinicalTrials.gov NCT03960541 · fetched Nov 12, 2026
- Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)PHASE3 · COMPLETED · started Apr 24, 2020ClinicalTrials.gov NCT04317040 · fetched Nov 12, 2026
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)PHASE2 · COMPLETED · started Sep 19, 2016ClinicalTrials.gov NCT02663622 · fetched Nov 12, 2026
- Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)PHASE1 · COMPLETED · started Jun 2, 2014ClinicalTrials.gov NCT02650895 · fetched Nov 12, 2026